Vabysmo®
Vabysmo® (faricimab) is one of the newest medications available for patients with wet AMD, diabetic macular edema, and retinal vein occlusion. What sets Vabysmo apart is that it targets not only VEGF, but also another pathway called Ang-2 (angiopoietin-2), which also contributes to blood vessel instability and leakage. By addressing both pathways, Vabysmo offers a broader approach to protecting vision.
How Vabysmo Works
VEGF drives the growth of abnormal, leaky blood vessels, while Ang-2 weakens normal vessel stability. Together, they cause swelling and retinal damage. Vabysmo is the first FDA-approved treatment to target both of these processes. This dual action helps reduce fluid buildup in the retina and prevent disease progression, with the potential benefit of longer intervals between treatments.
What to Expect During Treatment
The treatment process is similar to other injections. Your eye is numbed with anesthetic drops, and the injection takes only a few seconds. Mild irritation afterward is common but temporary. One of the key advantages of Vabysmo is that many patients are able to go longer between injections after the initial phase—sometimes every 12 to 16 weeks—while still maintaining excellent control of their condition.
Benefits of Vabysmo
The dual-pathway approach of Vabysmo may offer improved disease control compared to medications that only target VEGF. Longer treatment intervals can also reduce the burden of frequent office visits, making it easier for patients to stay on track with care.
At East Florida Eye Institute, we are proud to offer Vabysmo as part of our state-of-the-art retinal care. Our experienced team evaluates each patient’s unique condition and determines whether Vabysmo is the right choice. With advanced diagnostic imaging, personalized care plans, and a commitment to patient comfort, we ensure you receive the most effective and modern treatment available.